09 Aug. 2024
Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies – Solidifying its Position as a Leader in Complex LAI Products 
30 Apr. 2024
Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020
29 Apr. 2024
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American Thoracic Society International Conference
01 Apr. 2024
Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of CPP
08 Nov. 2023
Foresee Pharmaceuticals Announces Publication of Preclinical Data in the European Heart Journal Demonstrating the Therapeutic Potential of Foresee ALDH2 Activators in the Treatment of Heart Failure and Further Elucidating a Novel Mechanism of Action
30 Oct. 2023
